" class="no-js "lang="en-US"> Provention Bio Announces Appointment of Thierry Chauche as Chief Financial Officer - Medtech Alert
Friday, May 24, 2024

Provention Bio Announces Appointment of Thierry Chauche as Chief Financial Officer

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that Thierry Chauche will become Chief Financial Officer effective December 1, 2021 and Andrew Drechsler will be retiring, following a career of nearly 30 years in the financial and life sciences industry, most notably, the past four years at Provention Bio. Mr. Drechsler will continue to serve as a special advisor to the CEO and consultant through the middle of 2022.

“On behalf of the Board and our entire team, I would like to thank Andy for his foundational and ongoing contributions throughout these past four years as we’ve built Provention Bio from an idea into a company we believe is poised to change the therapeutic approach to serious autoimmune diseases from disease treatment to disease interception and prevention. Andy’s strategic vision, collaborative spirit and deeply personal connection to autoimmune disease has played such a crucial role in bringing us to this point in our corporate evolution,” stated Ashleigh Palmer, Chief Executive Officer & Co-Founder, Provention Bio. “I would also like to welcome Thierry to the Provention Bio team. His extensive commercial and strategic finance experience as well as his leadership skills are the perfect fit as we continue advancing to the next stage of our company’s growth.”

“It has been a privilege to spend the last four years working to help build a company with a mission so directly focused on needs that have a direct impact on my family,” stated Andrew Drechsler, Chief Financial Officer, Provention Bio. “As I begin the next chapter focused on my family’s careers and education as well as patient advocacy, I am confident in the future of Provention Bio and the potential impact it may have on the lives of so many affected by type 1 diabetes, celiac, and other autoimmune disorders.  I look forward to working together with Thierry to assist him and the Provention team with the transition.”

Thierry Chauche brings to Provention Bio a broad set of relevant financial experience and a strong track record of success over two decades. He joins from Alexion Pharmaceuticals where he was the Head of Strategic Financial Planning and Analysis. Prior to Alexion, Thierry served in roles of increasing responsibility at Intercept Pharmaceuticals, Novartis and Rothschild & Cie.  Mr. Chauche holds an M.S. in engineering from Ecole Des Ponts ParisTech and an M.B.A. from the Wharton School of the University of Pennsylvania.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more